1103500-32-8

Basic information

• Product Name: methyl5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazole-4-carboxylate
• Synonyms: methyl5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazole-4-carboxylate;EOS-60877;methyl 5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazole-4-carboxylate(WXFC0740)
• CAS NO: 1103500-32-8
• Molecular Formula: C₁₅H₁₂F₃NO₄
• Molecular Weight: 327.2552896
• Mol File: 1103500-32-8.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 379.8±42.0 °C(Predicted)
• Appearance: /
• Density: 1.380±0.06 g/cm3(Predicted)
• PKA: -4.75±0.50(Predicted)
• CAS DataBase Reference: methyl5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazole-4-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazole-4-carboxylate(1103500-32-8)
• EPA Substance Registry System: methyl5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazole-4-carboxylate(1103500-32-8)

Safety Data

• Hazardous Substances Data: 1103500-32-8(Hazardous Substances Data)

Upstream product

• 255820-47-4 2-(trifluoromethoxy)benzoaldehyde oxime 
• 32249-35-7 methyl 3-cyclopropyl-3-oxopropanoate 
• 543713-03-7 N-hydroxy-2-(trifluoromethoxy)benzimidonyl chloride 
• 1383740-00-8 (E)-2-(trifluoromethoxy)benzaldehyde oxime 
• 1383740-01-9 (Z)-N-hydroxy-2-(trifluoromethoxy)benzimidoyl chloride 
• 94651-33-9 2-(trifluoromethoxy)benzaldehyde 

Downstream Products

• 946427-86-7 4-(bromomethyl)-5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazole 
• 1383816-28-1 methyl-2-(3-((5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)methoxy)-8-azabicyclo[3.2.1]octan-8-yl)-4-fluorobenzo[d]thiazole-6-carboxylate 
• 1383816-29-2 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid 
• 1383816-32-7 methyl 2-(3-((5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)methoxy)-8-azabicyclo[3.2.1]octan-8-yl)-4-methoxybenzo[d]thiazole-6-carboxylate 
• 1383816-33-8 2-(3-((5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)methoxy)-8-azabicyclo[3.2.1]octan-8-yl)-4-methoxybenzo[d]thiazole-6-carboxylic acid 
• 1383816-93-0 methyl 5-cyclopropyl-6-((1S,3R)-3-((5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)methoxy)-8-azabicyclo[3.2.1]octan-8-yl)nicotinate 
• 1383816-94-1 5-cyclopropyl-6-((1S,3R)-3-((5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)methoxy)-8-azabicyclo[3.2.1]octan-8-yl)nicotinic acid 
• 1383822-31-8 (1R,3S,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octane 
• 1383824-64-3 methyl 6-(3-((5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)methoxy)-8-azabicyclo[3.2.1]octan-8-yl)benzo[d]isothiazole-3-carboxylate 
• 1383817-89-7 6-(3-((5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)methoxy)-8-azabicyclo[3.2.1]octan-8-yl)benzo[d]isothiazole-3-carboxylic acid 
• 1383739-48-7 ethyl 2-(4-((5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)methoxy)piperidin-1-yl)benzo[d]thiazole-6-carboxylate 
• 1103500-51-1 tert-butyl 4-((5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)methoxy)azepane-1-carboxylate 
• 1383739-76-1 C₃₀H₃₀F₃N₃O₅S 
• 1383739-49-8 2-(4-((5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)methoxy)piperidin-1-yl)benzo[d]thiazole-6-carboxylic acid 

Relevant articles and documents

COMPOSITIONS AND METHODS FOR TREATING LIVER DISORDERS

The present disclosure is directed to FXR agonists, pharmaceutical compositions thereof, and methods of using the same for preventing, treating, or ameliorating fatty liver diseases such as steatosis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis, either alone or in combination with thyroid receptor agonists.

Isoxazole FXR receptor agonist as well as preparation method and medical application thereof

The invention belongs to the field of medicinal chemistry, and particularly relates to an isoxazole FXR receptor agonist and a preparation method and medical application thereof. The invention relates to a compound as shown in a formula (I), and pharmaceutically acceptable salts and isotope markers thereof. The compound as shown in the formula (I), the pharmaceutically acceptable salts and the isotope markers thereof have FXR receptor agonist activity and can be applied to preparation of drugs for treating or preventing hyperlipidemia, atherosclerosis, non-alcoholic steatohepatitis and type II diabetes mellitus.

PPARs-FXR multi-target micromolecular agonist as well as preparation method and application thereof

The invention discloses a PPARs-FXR multi-target micromolecule agonist and a preparation method and application thereof, the structure is shown in a general formula I, and the definition of each substituent group is shown in the description and claims. Th